Fimasartan reduces clinic and home pulse pressure in elderly hypertensive patients: A K-Mets study

Eun Joo Cho, Ki Chul Sung, Seok Min Kang, Mi Seung Shin, Seung Jae Joo, Jeong Bae Park

Research output: Contribution to journalArticle

Abstract

Background Angiotensin II receptor blockers (ARBs) are recommended for treating patients with hypertension. However, comparative safety and efficacy of ARB use in elderly patients have not been well established. This study was designed to determine the efficacy of fimasartan, an ARB, in hypertensive elderly patients by measuring clinic and home blood pressures (BPs) and evaluating safety compared to nonelderly patients. Method In the K-MetS study, a nationwide prospective observational study of hypertensive patients on fimasartan, elderly patients (60 years and older) who were treated for 1 year with fimasartan were recruited. BP was evaluated in clinic and at home. Results Of the 6 399 enrolled patients, 2 363 were elderly (46.9% males, mean age 67.3 ± 5.7 years). Fimasartan reduced systolic and diastolic BP (SBP and DBP) in clinic from 144.1 ± 17.3 to 127.7 ± 12.9 mmHg and from 85.1 ± 10.4 to 76.8 ± 8.4 mmHg, respectively, (all p<0.0001) in 1 year. Similar results were found in home BPs. These BP changes were consistent with those in nonelderly patients. However, pulse pressure, a better predictor of cardiovascular events in the elderly, decreased more in elderly than in nonelderly patients by -8.2 ± 0.3 in elderly and -7.0 ± 0.2 mmHg (p<0.0001), respectively, after adjustment for confounding factors. Adverse events were reported in 1.6% of elderly hypertensives, independent of dose, which was consistent with results in nonelderly patients. Conclusions Fimasartan resulted in better pulse pressure reduction with similar BP reduction efficacy and safety in hypertensive elderly patients compared with nonelderly patients.

Original languageEnglish
Article numbere0214293
JournalPloS one
Volume14
Issue number4
DOIs
Publication statusPublished - 2019 Apr

Fingerprint

Blood pressure
Blood Pressure
Angiotensin Receptor Antagonists
blood pressure
angiotensin II
Safety
receptors
fimasartan
diastolic blood pressure
national surveys
systolic blood pressure
observational studies
hypertension
Observational Studies
Prospective Studies
Hypertension

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Cho, Eun Joo ; Sung, Ki Chul ; Kang, Seok Min ; Shin, Mi Seung ; Joo, Seung Jae ; Park, Jeong Bae. / Fimasartan reduces clinic and home pulse pressure in elderly hypertensive patients : A K-Mets study. In: PloS one. 2019 ; Vol. 14, No. 4.
@article{bfc496bedc0546e682ea20874833035d,
title = "Fimasartan reduces clinic and home pulse pressure in elderly hypertensive patients: A K-Mets study",
abstract = "Background Angiotensin II receptor blockers (ARBs) are recommended for treating patients with hypertension. However, comparative safety and efficacy of ARB use in elderly patients have not been well established. This study was designed to determine the efficacy of fimasartan, an ARB, in hypertensive elderly patients by measuring clinic and home blood pressures (BPs) and evaluating safety compared to nonelderly patients. Method In the K-MetS study, a nationwide prospective observational study of hypertensive patients on fimasartan, elderly patients (60 years and older) who were treated for 1 year with fimasartan were recruited. BP was evaluated in clinic and at home. Results Of the 6 399 enrolled patients, 2 363 were elderly (46.9{\%} males, mean age 67.3 ± 5.7 years). Fimasartan reduced systolic and diastolic BP (SBP and DBP) in clinic from 144.1 ± 17.3 to 127.7 ± 12.9 mmHg and from 85.1 ± 10.4 to 76.8 ± 8.4 mmHg, respectively, (all p<0.0001) in 1 year. Similar results were found in home BPs. These BP changes were consistent with those in nonelderly patients. However, pulse pressure, a better predictor of cardiovascular events in the elderly, decreased more in elderly than in nonelderly patients by -8.2 ± 0.3 in elderly and -7.0 ± 0.2 mmHg (p<0.0001), respectively, after adjustment for confounding factors. Adverse events were reported in 1.6{\%} of elderly hypertensives, independent of dose, which was consistent with results in nonelderly patients. Conclusions Fimasartan resulted in better pulse pressure reduction with similar BP reduction efficacy and safety in hypertensive elderly patients compared with nonelderly patients.",
author = "Cho, {Eun Joo} and Sung, {Ki Chul} and Kang, {Seok Min} and Shin, {Mi Seung} and Joo, {Seung Jae} and Park, {Jeong Bae}",
year = "2019",
month = "4",
doi = "10.1371/journal.pone.0214293",
language = "English",
volume = "14",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

Fimasartan reduces clinic and home pulse pressure in elderly hypertensive patients : A K-Mets study. / Cho, Eun Joo; Sung, Ki Chul; Kang, Seok Min; Shin, Mi Seung; Joo, Seung Jae; Park, Jeong Bae.

In: PloS one, Vol. 14, No. 4, e0214293, 04.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fimasartan reduces clinic and home pulse pressure in elderly hypertensive patients

T2 - A K-Mets study

AU - Cho, Eun Joo

AU - Sung, Ki Chul

AU - Kang, Seok Min

AU - Shin, Mi Seung

AU - Joo, Seung Jae

AU - Park, Jeong Bae

PY - 2019/4

Y1 - 2019/4

N2 - Background Angiotensin II receptor blockers (ARBs) are recommended for treating patients with hypertension. However, comparative safety and efficacy of ARB use in elderly patients have not been well established. This study was designed to determine the efficacy of fimasartan, an ARB, in hypertensive elderly patients by measuring clinic and home blood pressures (BPs) and evaluating safety compared to nonelderly patients. Method In the K-MetS study, a nationwide prospective observational study of hypertensive patients on fimasartan, elderly patients (60 years and older) who were treated for 1 year with fimasartan were recruited. BP was evaluated in clinic and at home. Results Of the 6 399 enrolled patients, 2 363 were elderly (46.9% males, mean age 67.3 ± 5.7 years). Fimasartan reduced systolic and diastolic BP (SBP and DBP) in clinic from 144.1 ± 17.3 to 127.7 ± 12.9 mmHg and from 85.1 ± 10.4 to 76.8 ± 8.4 mmHg, respectively, (all p<0.0001) in 1 year. Similar results were found in home BPs. These BP changes were consistent with those in nonelderly patients. However, pulse pressure, a better predictor of cardiovascular events in the elderly, decreased more in elderly than in nonelderly patients by -8.2 ± 0.3 in elderly and -7.0 ± 0.2 mmHg (p<0.0001), respectively, after adjustment for confounding factors. Adverse events were reported in 1.6% of elderly hypertensives, independent of dose, which was consistent with results in nonelderly patients. Conclusions Fimasartan resulted in better pulse pressure reduction with similar BP reduction efficacy and safety in hypertensive elderly patients compared with nonelderly patients.

AB - Background Angiotensin II receptor blockers (ARBs) are recommended for treating patients with hypertension. However, comparative safety and efficacy of ARB use in elderly patients have not been well established. This study was designed to determine the efficacy of fimasartan, an ARB, in hypertensive elderly patients by measuring clinic and home blood pressures (BPs) and evaluating safety compared to nonelderly patients. Method In the K-MetS study, a nationwide prospective observational study of hypertensive patients on fimasartan, elderly patients (60 years and older) who were treated for 1 year with fimasartan were recruited. BP was evaluated in clinic and at home. Results Of the 6 399 enrolled patients, 2 363 were elderly (46.9% males, mean age 67.3 ± 5.7 years). Fimasartan reduced systolic and diastolic BP (SBP and DBP) in clinic from 144.1 ± 17.3 to 127.7 ± 12.9 mmHg and from 85.1 ± 10.4 to 76.8 ± 8.4 mmHg, respectively, (all p<0.0001) in 1 year. Similar results were found in home BPs. These BP changes were consistent with those in nonelderly patients. However, pulse pressure, a better predictor of cardiovascular events in the elderly, decreased more in elderly than in nonelderly patients by -8.2 ± 0.3 in elderly and -7.0 ± 0.2 mmHg (p<0.0001), respectively, after adjustment for confounding factors. Adverse events were reported in 1.6% of elderly hypertensives, independent of dose, which was consistent with results in nonelderly patients. Conclusions Fimasartan resulted in better pulse pressure reduction with similar BP reduction efficacy and safety in hypertensive elderly patients compared with nonelderly patients.

UR - http://www.scopus.com/inward/record.url?scp=85064089590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064089590&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0214293

DO - 10.1371/journal.pone.0214293

M3 - Article

C2 - 30964905

AN - SCOPUS:85064089590

VL - 14

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0214293

ER -